title: Marrow-ablative treatment and autologous stem cell transplantation in follicular NHL.
abstract: High-dose therapy followed by autologous stem cell transplantation is widely accepted as salvage therapy for patients with relapsed aggressive lymphoma. In the pre-rituximab era, autologous stem cell transplantation had also been increasingly applied as a consolidation treatment for patients with indolent lymphoma in second or subsequent remission whereas controversies have emerged concerning its role in first line therapy from several randomized trials. Broad development and amazing efficacy of monoclonal antibody-based combination therapies for de novo or relapsing follicular lymphoma patients render previous conclusions outdated and underline the critical need for further phase III trials. This review focuses on available data from pre-rituximab and rituximab eras to help clarifying the precise role and timing of autologous stem cell transplantation among the current armamentarium for follicular lymphoma treatment.
authors.affiliation: Hospices Civils de Lyon and Université Claude Bernard Lyon 1, Pierre Bénite 69495, France.
authors.forename: Emmanuel
authors.initials: E
authors.lastname: Bachy
authors.forename: Gilles
authors.initials: G
authors.lastname: Salles
mesh_terms: D000818:Animals; D058846:Antibodies, Monoclonal, Murine-Derived / Q000276:immunology / Q000627:therapeutic use*; D001853:Bone Marrow / Q000187:drug effects / Q000473:pathology; D017326:Clinical Trials, Phase III as Topic; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D018796:Immunoconjugates / Q000627:therapeutic use*; D007167:Immunotherapy / Q000379:methods*; D008224:Lymphoma, Follicular / Q000276:immunology / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D051379:Mice; D019653:Myeloablative Agonists / Q000008:administration & dosage; D016032:Randomized Controlled Trials as Topic; D012008:Recurrence; D012074:Remission Induction; D000069283:Rituximab; D016879:Salvage Therapy / Q000379:methods*; D015996:Survival Rate; D014182:Transplantation, Autologous
chemical_list: D058846:Antibodies, Monoclonal, Murine-Derived; D018796:Immunoconjugates; D019653:Myeloablative Agonists; D000069283:Rituximab